LINCOLNSHIRE, Ill.--(BUSINESS WIRE)--BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) today announced it has signed a license agreement covering the use of BioSante’s patented calcium phosphate nanotechnology (CaP) as a facial filler (BioLook™) in aesthetic medicine. The license was signed with Medical Aesthetics Technology Corporation (“MATC”) with whom BioSante has been working in the field of aesthetic medicine. This license agreement is a result of MATC’s exercise of a previously signed option agreement. Under the agreement, MATC is responsible for continued development of BioLook, including required clinical trials, regulatory filings and all manufacturing and marketing associated with the product.
